New Novartis Phase II data show LCZ696 may provide clinical benefits in ... Reuters Novartis International AG / New Novartis Phase II data show LCZ696 may provide clinical benefits in patients with a difficult-to-treat form of heart failure . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the ... |
